

a labeled ( $^{14}\text{C}$ -L-leucine) melanoma (UCLA-SO-M14) cells with human [polyclonal antibody] serum as the source of antibodies. The [antibody was] antibodies were used before (A) and after (B) pretreatment with purified U-TAA. The radioactivity profile was determined by analyzing the radioactivity in 1.0 mm slices of each lane of the gel. Pretreatment of the antibodies (B) showed fewer radioactive peaks, particularly in the 150 to 60 KD and 45 KD regions.

On page 4, line 4, change "cell" to --cells--.

On page 4, line 28, after "In", insert --a--.

On page 5, line 14, after "sizes," insert --the--.

On page 6, line 8, change "asses" to --assess--.

On page 6, line 14, after "Again" insert --,--.

On page 24, line 2, change "eluent" to --eluant--.

On page 25, line 35 and on page 55, line 32, change "Nonadet" to --Nonidet--.

On page 36, line 26, after "of" insert --the--.

On page 40, line 19, change "Eptitope" to --Epitope--.

On page 54, line 35, change "hepranized" to --heparinized--.

On page 60, line 31, change "had" to --have--.